Immix Biopharma, Inc. cotiza a 9.25 USD y tiene una capitalización bursátil de $767M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.18 | $-0.18 | $-0.28 |
| Estimado | $-0.19 | $-0.18 | $-0.21 | $-0.16 |
| Sorpresa | — | +0.0% | +14.3% | -75.0% |
| Métrica | IMMX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -31.4% | -40.4% | +9.0% |
| ROA | -28.1% | -32.0% | +3.9% |
| Current Ratio | 10.01 | 2.84 | +7.17 |
| Debt / Equity | — | 0.28 | — |